Olympia and Wesley Pharmaceuticals Appoints Joshua Fritzler as President Across Both 503B Facilities

As 503B outsourcing facilities face mounting pressure to scale compounding operations under tightening FDA oversight, Olympia and Wesley Pharmaceuticals has promoted Joshua Fritzler from CFO to President, consolidating executive leadership across both Orlando-based facilities.

Fritzler joined Olympia in 2021 and has since been central to the operational build-out that produced Wesley Pharmaceuticals, a sister 503B facility co-founded by Stan and Naomi Loomis in 2024. His tenure spanned a period of rapid demand growth in weight management compounding, during which he oversaw production capacity expansion and process streamlining across both sites. Wesley, the newer of the two facilities, targets therapeutic areas including weight management, hormone replacement therapy, and wellness.

For QA directors and regulatory affairs leads at compounding operations, the appointment reflects a broader pattern in the sector: finance-trained executives moving into operational leadership as 503B facilities mature from startup-phase compounders into structured, GMP-aligned manufacturers. Fritzler's background in financial oversight positions him to manage the capital allocation decisions that accompany sustained volume growth, particularly as GLP-1 demand continues to stress compounding supply chains.

Olympia holds FDA registration as a 503B outsourcing facility and distributes compounded medications to 49 states for both office use and patient-specific prescriptions. Its therapeutic focus includes weight loss, dermatology, IV nutritional therapy, and erectile dysfunction. Wesley operates under the same Orlando footprint and ownership structure, with a stated mandate to expand across additional therapeutic categories.

Founders Stan and Naomi Loomis cited Fritzler's role in guiding the organization through regulatory and operational complexity as the basis for the promotion. No structural changes to the compliance or quality functions at either facility were disclosed alongside the appointment.

How Fritzler allocates leadership attention between Olympia's established 503B operations and Wesley's still-scaling facility will serve as a near-term indicator of whether the consolidated presidency model strengthens or strains quality system oversight across both sites.

Source: Olympia and Wesley Pharmaceuticals via GlobeNewswire, May 19, 2026.